All In Biotech

Drug Trial Radar · NCT02080364

Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease

Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine

Last checked: Nov 20, 2026Latest source record: May 7, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 880 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

880

Actual

Start

Apr 2015

Primary completion

Jun 1, 2018

Study completion Jun 1, 2018

Sponsor

Lead sponsor
vTv TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 6, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.

Conditions

  • Alzheimer's Disease

Interventions

  • AzeliragonDrug

    Azeliragon 5mg administered orally, once daily for 18 months

  • PlaceboDrug

    Placebo administered orally, once daily for 18 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Total ScoreTime frame: Baseline and 18 months (A-Study); baseline and 12 months (B-Study)
  2. Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)Time frame: Baseline and 18 months (A-Study); baseline and 12 months (B-Study)

Locations

115 sites in 7 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Bellflower, California

  • Site not named

    Costa Mesa, California

  • Site not named

    Fullerton, California

  • Site not named

    Glendale, California

  • Site not named

    Imperial, California

  • Site not named

    Irvine, California

  • Site not named

    Laguna Hills, California

  • Site not named

    Long Beach, California

  • Site not named

    Long Beach, California

  • Site not named

    Orange, California

  • Site not named

    Riverside, California

  • Site not named

    San Bernardino, California

  • Site not named

    San Francisco, California

  • Site not named

    Santa Ana, California

  • Site not named

    Atlantis, Florida

  • Site not named

    Brooksville, Florida

  • Site not named

    Delray Beach, Florida

  • Site not named

    Hallandale, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Lake Worth, Florida

  • Site not named

    Leesburg, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Miami Beach, Florida

  • Site not named

    Miami Lakes, Florida

  • Site not named

    Miami Lakes, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Pensacola, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Sunrise, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Columbus, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Fairway, Kansas

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.